172 related articles for article (PubMed ID: 20212519)
1. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.
Leskelä S; Jara C; Leandro-García LJ; Martínez A; García-Donas J; Hernando S; Hurtado A; Vicario JC; Montero-Conde C; Landa I; López-Jiménez E; Cascón A; Milne RL; Robledo M; Rodríguez-Antona C
Pharmacogenomics J; 2011 Apr; 11(2):121-9. PubMed ID: 20212519
[TBL] [Abstract][Full Text] [Related]
2. Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.
Lee MY; Apellániz-Ruiz M; Johansson I; Vikingsson S; Bergmann TK; Brøsen K; Green H; Rodríguez-Antona C; Ingelman-Sundberg M
Pharmacogenomics; 2015; 16(9):929-37. PubMed ID: 26115084
[TBL] [Abstract][Full Text] [Related]
3. CYP1A1, CYP3A5 and CYP3A7 polymorphisms and testicular cancer susceptibility.
Kristiansen W; Haugen TB; Witczak O; Andersen JM; Fosså SD; Aschim EL
Int J Androl; 2011 Feb; 34(1):77-83. PubMed ID: 20345875
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.
Bergmann TK; Brasch-Andersen C; Gréen H; Mirza M; Pedersen RS; Nielsen F; Skougaard K; Wihl J; Keldsen N; Damkier P; Friberg LE; Peterson C; Vach W; Karlsson MO; Brosen K
Pharmacogenomics J; 2011 Apr; 11(2):113-20. PubMed ID: 20368717
[TBL] [Abstract][Full Text] [Related]
5. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
6. Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation.
Rowbotham SE; Boddy AV; Redfern CP; Veal GJ; Daly AK
Drug Metab Dispos; 2010 Aug; 38(8):1261-6. PubMed ID: 20421446
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel.
Hanioka N; Matsumoto K; Saito Y; Narimatsu S
Basic Clin Pharmacol Toxicol; 2010 Jul; 107(1):565-9. PubMed ID: 20148860
[TBL] [Abstract][Full Text] [Related]
8. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients.
Rizzo R; Spaggiari F; Indelli M; Lelli G; Baricordi OR; Rimessi P; Ferlini A
Breast Cancer Res Treat; 2010 Nov; 124(2):593-8. PubMed ID: 20632082
[TBL] [Abstract][Full Text] [Related]
9. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.
Hertz DL; Motsinger-Reif AA; Drobish A; Winham SJ; McLeod HL; Carey LA; Dees EC
Breast Cancer Res Treat; 2012 Jul; 134(1):401-10. PubMed ID: 22527101
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer.
Alcazar-González GA; Calderón-Garcidueñas AL; Garza-Rodríguez ML; Rubio-Hernández G; Escorza-Treviño S; Olano-Martin E; Cerda-Flores RM; Castruita-Avila AL; González-Guerrero JF; le Brun S; Simon-Buela L; Barrera-Saldaña HA
Pharmacogenomics; 2013 Oct; 14(13):1583-92. PubMed ID: 24088129
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of paclitaxel metabolism.
Spratlin J; Sawyer MB
Crit Rev Oncol Hematol; 2007 Mar; 61(3):222-9. PubMed ID: 17092739
[TBL] [Abstract][Full Text] [Related]
12. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Henningsson A; Marsh S; Loos WJ; Karlsson MO; Garsa A; Mross K; Mielke S; Viganò L; Locatelli A; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2005 Nov; 11(22):8097-104. PubMed ID: 16299241
[TBL] [Abstract][Full Text] [Related]
13. Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.
Gréen H; Khan MS; Jakobsen-Falk I; Åvall-Lundqvist E; Peterson C
J Pharm Sci; 2011 Oct; 100(10):4205-9. PubMed ID: 21702053
[TBL] [Abstract][Full Text] [Related]
14. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.
Fransson MN; Gréen H; Litton JE; Friberg LE
Drug Metab Dispos; 2011 Feb; 39(2):247-55. PubMed ID: 21056987
[TBL] [Abstract][Full Text] [Related]
15. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.
Martínez C; García-Martín E; Pizarro RM; García-Gamito FJ; Agúndez JA
Br J Cancer; 2002 Sep; 87(6):681-6. PubMed ID: 12237780
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.
Frederiks CN; Lam SW; Guchelaar HJ; Boven E
Cancer Treat Rev; 2015 Dec; 41(10):935-50. PubMed ID: 26585358
[TBL] [Abstract][Full Text] [Related]
17. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer.
Pan JH; Han JX; Wu JM; Sheng LJ; Huang HN; Yu QZ
Respiration; 2008; 75(4):380-5. PubMed ID: 17851225
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
Bosch TM; Huitema AD; Doodeman VD; Jansen R; Witteveen E; Smit WM; Jansen RL; van Herpen CM; Soesan M; Beijnen JH; Schellens JH
Clin Cancer Res; 2006 Oct; 12(19):5786-93. PubMed ID: 17020985
[TBL] [Abstract][Full Text] [Related]
19. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
[TBL] [Abstract][Full Text] [Related]
20. Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma.
Bergmann TK; Filppula AM; Launiainen T; Nielsen F; Backman J; Brosen K
Br J Clin Pharmacol; 2016 Feb; 81(2):313-5. PubMed ID: 26446447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
